GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASLAN Pharmaceuticals Ltd (NAS:ASLN) » Definitions » Cash Conversion Cycle

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Cash Conversion Cycle : 0.00 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ASLAN Pharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

ASLAN Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.
ASLAN Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 was 0.
ASLAN Pharmaceuticals's Days Payable for the three months ended in Mar. 2024 was 0.
Therefore, ASLAN Pharmaceuticals's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 0.00.


ASLAN Pharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for ASLAN Pharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASLAN Pharmaceuticals Cash Conversion Cycle Chart

ASLAN Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,223.12 - - - -

ASLAN Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 91.25 - - -

Competitive Comparison of ASLAN Pharmaceuticals's Cash Conversion Cycle

For the Biotechnology subindustry, ASLAN Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ASLAN Pharmaceuticals's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ASLAN Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where ASLAN Pharmaceuticals's Cash Conversion Cycle falls into.



ASLAN Pharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

ASLAN Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+0-0
=0.00

ASLAN Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ASLAN Pharmaceuticals  (NAS:ASLN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


ASLAN Pharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of ASLAN Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
3 Temasek Avenue, Level 18, Centennial Tower, Singapore, SGP, 039190
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Headlines

From GuruFocus